Shilpa patents expiration
1. Docetaxel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10842770 | SHILPA | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
Aug, 2031
(7 years from now) | |
| US8940786 | SHILPA | Non-aqueous taxane nanodispersion formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
| US9308195 | SHILPA | Non-aqueous taxane formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
| US9763880 | SHILPA | Non-aqueous taxane formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
Drugs and Companies using DOCETAXEL ingredient
Market Authorisation Date: 22 December, 2015
Treatment: Method of administering docetaxel to a subject combining the docetaxel pro-emulsion formulation with an aqueous medium to produce docetaxel emulsion; Method of administering an ethanol-free taxane liq...
Dosage: INJECTABLE;INJECTION
More Information on Dosage
DOCETAXEL family patents
2. Pemetrexed patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11147817 | SHILPA | Pharmaceutical composition of pemetrexed |
Mar, 2035
(10 years from now) | |
Drugs and Companies using PEMETREXED DISODIUM ingredient
Market Authorisation Date: 22 May, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
PEMETREXED family patents